MA54460A - Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine - Google Patents
Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridineInfo
- Publication number
- MA54460A MA54460A MA054460A MA54460A MA54460A MA 54460 A MA54460 A MA 54460A MA 054460 A MA054460 A MA 054460A MA 54460 A MA54460 A MA 54460A MA 54460 A MA54460 A MA 54460A
- Authority
- MA
- Morocco
- Prior art keywords
- water
- pharmaceutical formulations
- based pharmaceutical
- dihydropyridine compounds
- dihydropyridine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779620P | 2018-12-14 | 2018-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54460A true MA54460A (fr) | 2021-10-20 |
Family
ID=69174604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054460A MA54460A (fr) | 2018-12-14 | 2019-12-16 | Formulations pharmaceutiques à base d'eau de composés de 1,2-dihydropyridine |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12303499B2 (fr) |
| EP (1) | EP3893844A1 (fr) |
| JP (1) | JP7177937B2 (fr) |
| KR (1) | KR102912861B1 (fr) |
| CN (1) | CN113226286B (fr) |
| AU (1) | AU2019395288B2 (fr) |
| BR (1) | BR112021010953A2 (fr) |
| CA (1) | CA3122705A1 (fr) |
| MA (1) | MA54460A (fr) |
| MX (1) | MX2021006317A (fr) |
| WO (1) | WO2020124090A1 (fr) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356902A (en) | 1992-11-06 | 1994-10-18 | Eli Lilly And Company | Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists |
| IL109397A0 (en) | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| HU219777B (hu) | 1993-07-02 | 2001-07-30 | Gyógyszerkutató Intézet Kft. | Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására |
| DK0784054T3 (da) | 1994-09-27 | 2002-03-25 | Yamanouchi Pharma Co Ltd | 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister |
| US5935551A (en) | 1995-11-15 | 1999-08-10 | California Institute Of Technology | Synthesis of zeolites by hydrothermal reaction of zeolite P1 |
| DE19604920A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
| HU9600871D0 (en) | 1996-04-04 | 1996-05-28 | Gyogyszerkutato Intezet | New 2,3-benzodiazepine derivatives |
| CN1103772C (zh) | 1996-05-15 | 2003-03-26 | 辉瑞大药厂 | 新的2,3-二取代-4(3h)-喹唑啉酮类化合物 |
| DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| SK113299A3 (en) | 1997-02-28 | 2001-05-10 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists |
| GB9711753D0 (en) | 1997-06-06 | 1997-08-06 | Merck Sharp & Dohme | Therapeutic agents |
| WO2000001376A2 (fr) | 1998-07-02 | 2000-01-13 | Eisai Co., Ltd | Compositions pharmaceutiques et leur utilisation |
| DE19835918A1 (de) | 1998-08-07 | 2000-02-10 | Dresden Arzneimittel | Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung |
| ES2320973T3 (es) | 2000-06-12 | 2009-06-01 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos. |
| GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
| US7803818B2 (en) | 2005-12-21 | 2010-09-28 | Eisai R&D Management Co., Ltd. | Amorphous form of 1,2-dihydropyridine compound |
| WO2008111590A2 (fr) | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | Antagonistes des récepteurs ampa et nmda pour maladies neurodégénératives |
| JP2015227288A (ja) * | 2012-08-31 | 2015-12-17 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | けいれん重積発作の治療用医薬組成物 |
| CN104644592A (zh) * | 2013-11-25 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 一种吡仑帕奈药物组合物及其制备方法 |
| CN104706604A (zh) * | 2013-12-12 | 2015-06-17 | 北京星昊医药股份有限公司 | 一种吡仑帕奈冻干口崩片及其制备方法 |
| CA2973140C (fr) * | 2015-02-06 | 2025-09-16 | Marinus Pharmaceuticals, Inc. | Formulations de ganaxolone intraveineuses et leur utilisation dans le traitement d'un etat de mal epileptique et d'autres troubles epileptiques |
| CN106389367B (zh) | 2016-11-16 | 2020-12-18 | 杭州朱养心药业有限公司 | 吡仑帕奈包衣片剂药物组合物 |
| WO2018169798A1 (fr) | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Atténuation de troubles du snc par polythérapie faisant intervenir des neurostéroïdes, et des bloqueurs ampa |
-
2019
- 2019-12-16 MA MA054460A patent/MA54460A/fr unknown
- 2019-12-16 KR KR1020217017514A patent/KR102912861B1/ko active Active
- 2019-12-16 CA CA3122705A patent/CA3122705A1/fr active Pending
- 2019-12-16 WO PCT/US2019/066622 patent/WO2020124090A1/fr not_active Ceased
- 2019-12-16 CN CN201980081856.7A patent/CN113226286B/zh active Active
- 2019-12-16 AU AU2019395288A patent/AU2019395288B2/en active Active
- 2019-12-16 JP JP2021530970A patent/JP7177937B2/ja active Active
- 2019-12-16 EP EP19839214.4A patent/EP3893844A1/fr active Pending
- 2019-12-16 US US17/312,077 patent/US12303499B2/en active Active
- 2019-12-16 BR BR112021010953-6A patent/BR112021010953A2/pt unknown
- 2019-12-16 MX MX2021006317A patent/MX2021006317A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019395288A1 (en) | 2021-09-23 |
| CN113226286B (zh) | 2024-08-20 |
| WO2020124090A1 (fr) | 2020-06-18 |
| AU2019395288B2 (en) | 2025-04-03 |
| US20220023275A1 (en) | 2022-01-27 |
| US12303499B2 (en) | 2025-05-20 |
| KR20210107644A (ko) | 2021-09-01 |
| KR102912861B1 (ko) | 2026-01-15 |
| JP7177937B2 (ja) | 2022-11-24 |
| MX2021006317A (es) | 2021-08-11 |
| EP3893844A1 (fr) | 2021-10-20 |
| JP2022510947A (ja) | 2022-01-28 |
| CN113226286A (zh) | 2021-08-06 |
| BR112021010953A2 (pt) | 2021-08-24 |
| CA3122705A1 (fr) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52421A (fr) | Composés pharmaceutiques | |
| EP3442973A4 (fr) | Nouveaux composés utilisés en tant qu'inhibiteurs de l'autotaxine et compositions pharmaceutiques les comprenant | |
| IL283134A (en) | Alcohol-resistant drug formulations | |
| EP3843704A4 (fr) | Formulations d'émulsion d'inhibiteurs de multikinase | |
| EP3328843A4 (fr) | Composés dérivés de 1,3,4-oxadiazole sulfonamide servant d'inhibiteur de l'histone désacétylase 6, et composition pharmaceutique comprenant ceux-ci | |
| MA46466A (fr) | Formulations pharmaceutiques de protéines à viscosité réduite | |
| MX378806B (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas. | |
| EP3256149A4 (fr) | Formulations pour administration orale d'agents actifs | |
| MX2020011478A (es) | Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos. | |
| EP3405183A4 (fr) | Dérivés d'adamatane pour le traitement d'une infection à filovirus | |
| MA49393A (fr) | Poly(phosphoesters) destinés à l'administration d'acides nucléiques | |
| MA55015A (fr) | Formulations pharmaceutiques | |
| MA50356A (fr) | Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 | |
| MA50250A (fr) | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 | |
| EP3399979A4 (fr) | Formulations de 2-(4-chlorophényl)-n-((2-(2,6-dioxopipéridin-3-yl)-1-oxoisoindolin-5-yl)méthyl)-2,2-difluoroacétamide | |
| EP3897593A4 (fr) | Formulations de cannabinoïdes et compositions pharmaceutiques | |
| EP3917926A4 (fr) | Dérivés d'imidazoquinoline amine, composition pharmaceutique, utilisation de ceux-ci | |
| EP3914234A4 (fr) | Compositions pharmaceutiques | |
| EP3880671A4 (fr) | Nouveau composé utilisé en tant qu'inhibiteur de protéine kinase, et composition pharmaceutique le comprenant | |
| MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale | |
| EP4015001A4 (fr) | Composition pharmaceutique orale | |
| EP3452441A4 (fr) | Dérivés d'acide alpha-truxillique et compositions pharmaceutiques associées | |
| EP3677652A4 (fr) | Composition d'encre à base d'eau | |
| EP3976025A4 (fr) | Formulations d'agents d'imagerie psma | |
| EP3582759A4 (fr) | Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine |